{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:09:00Z","timestamp":1779192540065,"version":"3.51.4"},"reference-count":96,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T00:00:00Z","timestamp":1454025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pressurized metered-dose inhalers (pMDIs) are sometimes viewed as old-fashioned and as having been superseded by dry powder inhalers (DPIs). Here, we review the technological advances that characterize modern pMDIs, and consider how they can influence the effectiveness of drug delivery for patients with asthma and chronic obstructive pulmonary disease. Compared with old chlorofluorocarbon (CFC)-based inhalers, many hydrofluoroalkane (HFA)-driven pMDIs have more favorable plume characteristics such as a reduced velocity and a higher fine particle fraction; together, these advances have resulted in the development of pMDIs with reduced oropharyngeal deposition and increased lung deposition. In addition, the plume from many HFA-pMDIs is warmer, which may facilitate their use by patients; moreover, devices are equipped with dose counters, which improves their reliability. As well as reviewing the technological advances of pMDIs, we also discuss the importance of individualizing inhaler therapies to each patient by accounting for their personal preferences and natural breathing patterns. Because pMDIs and DPIs differ considerably in their handling characteristics, matching the right inhaler to the right patient is key to ensuring effective therapy and good compliance. Finally, the majority of patients can be trained successfully in the correct use of their pMDI; training and regular monitoring of inhalation technique are essential prerequisites for effective therapy. While the \u2018ideal inhaler\u2019 may not exist, pMDIs are an effective device option suitable for many patients. pMDIs, together with other types of devices, offer opportunities for the effective individualization of treatments.<\/jats:p>","DOI":"10.1089\/jamp.2015.1232","type":"journal-article","created":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T16:12:28Z","timestamp":1454083948000},"page":"311-327","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":62,"title":["The Evolution of Pressurized Metered-Dose Inhalers from Early to Modern Devices"],"prefix":"10.1177","volume":"29","author":[{"given":"Nicolas","family":"Roche","sequence":"first","affiliation":[{"name":"University Paris Descartes","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.N. Richard","family":"Dekhuijzen","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre","place":["Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,1,29]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.3.215"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05501201"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.03.012"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.941"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3132\/pcrj.2007.00017"},{"key":"e_1_3_4_7_2","unstructured":"Sales-Girons J: \u00c9tude m\u00e9dicale et historique des eaux min\u00e9rales sulfureuses d'Enghien-Les-Bains: Application des eaux sulfureuses pulv\u00e9ris\u00e9es au traitement des malades de poitrine. Paris: Delahaye 1864:1\u2013190. Available at: https:\/\/ia600800.us.archive.org\/30\/items\/39002086471225.med.yale.edu\/39002086471225.med.yale.edu.pdf; Accessed April3 2015)."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05501139"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcrj.2006.09.002"},{"key":"e_1_3_4_10_2","first-page":"145","article-title":"Development of Respimat\u00ae Soft Mist Inhaler and its clinical utility in respiratory disorders","volume":"4","author":"Dalby RN","year":"2011","unstructured":"Dalby RN, , Eicher J, , and Zierenberg B: Development of Respimat\u00ae Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011; 4:145\u2013155.","journal-title":"Med Devices (Auckl)"},{"key":"e_1_3_4_11_2","first-page":"101","article-title":"Problems patients have using pressurized aerosol inhalers","volume":"119","author":"Crompton GK","year":"1982","unstructured":"Crompton GK: Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl. 1982; 119:101\u2013104.","journal-title":"Eur J Respir Dis Suppl"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90211-6"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200409-046TA"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2007.0643"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00166410"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/08942680150506303"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948060-00001"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2.2.161"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70016-3"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-504X.2005.00721.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90040-3"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05501209"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13556-013-0003-9"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13556-013-0006-6"},{"key":"e_1_3_4_25_2","article-title":"Letter in response to the review by De Maria et al. 2014","volume":"4","author":"Johal B","year":"2014","unstructured":"Johal B, , Howald M, , Fischer M, , Marshall J, , and Venthoye G: Letter in response to the review by De Maria et al. 2014. Comb Prod Ther. 2014; 4:doi: 10.1007\/s13556-13014-10007-13550.","journal-title":"Comb Prod Ther"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003\/erj.44.Suppl_58.P955"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05501304"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-6155-x"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(99)00133-7"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/102418"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/jam.2005.18.273"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.11.037"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","unstructured":"Johal B Murphy S and Marshall J: Plume characteristics of fluticasone propionate\/formoterol pMDI compared with fluticasone propionate\/salmeterol pMDI. Presented at the European Respiratory Society Annual Congress Barcelona Spain 7\u201311 September 2013.","DOI":"10.1183\/13993003\/erj.42.Suppl_57.P4132"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.2.510"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/08958378.2011.644351"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2009.0772"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","unstructured":"Van Holsbeke C Marshall J De Backer J and Vos W: In vitro lung deposition of fluticasone propionate\/formoterol (FP\/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles. Presented at the European Respiratory Society Annual Congress 2014.","DOI":"10.1183\/13993003\/erj.44.Suppl_58.P910"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","unstructured":"De Backer J Van Holsbeke C Vos W Vinchurkar S Rebello J Mangale M and De Backer W: Lung deposition analysis of two formulations of flutciasone\/salmeterol HFA pMDI in stable asthma patients. Presented at the European Respiratory Society Annual Congress Munich Germany 2014.","DOI":"10.1183\/13993003\/erj.44.Suppl_58.P3330"},{"key":"e_1_3_4_39_2","unstructured":"Global Initiative for Asthma: Global strategy for asthma management and prevention 2014. Available at: http:\/\/www.ginasthma.org\/. Accessed April3 2015."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.04.012"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00218402"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.09.013"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2009.00069"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.01.005"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/02770900701815727"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2009.0785"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.07.004"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1071\/HC13191"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2009.00029"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00150910"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","unstructured":"Van Holsbeke C Marshall J De Backer J and Vos W: The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI). Presented at the European Respiratory Society Annual Congress 2014.","DOI":"10.1183\/13993003\/erj.44.Suppl_58.P911"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02499.x"},{"key":"e_1_3_4_53_2","first-page":"57","article-title":"Effects of various inhalation modes on the deposition of radioactive pressurized aerosols","volume":"119","author":"Newman SP","year":"1982","unstructured":"Newman SP, , Pavia D, , Garland N, , and Clarke SW: Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl. 1982; 119:57\u201365.","journal-title":"Eur J Respir Dis Suppl"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200410-1414OC"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.14510349"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2012.4.4.184"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2014.854168"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.46.10.712"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1089\/089426803769017613"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.4.957"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1089\/jam.2005.18.264"},{"key":"e_1_3_4_62_2","first-page":"233","article-title":"Inhalatory therapy training: A priority challenge for the physician","volume":"78","author":"Melani AS","year":"2007","unstructured":"Melani AS: Inhalatory therapy training: A priority challenge for the physician. Acta Biomed. 2007; 78:233\u2013245.","journal-title":"Acta Biomed"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2013.876650"},{"issue":"3","key":"e_1_3_4_64_2","first-page":"1","article-title":"Patient handling study of fluticasone propionate\/formoterol fumarate pressurized metered-dose inhaler","volume":"19","author":"Bell D","year":"2014","unstructured":"Bell D, , Mansfield L, , Lomax M, , and Dissanayake S: Patient handling study of fluticasone propionate\/formoterol fumarate pressurized metered-dose inhaler. Respirology. 2014; 19(Suppl 3):1\u201362 Abstract O-A-016.","journal-title":"Respirology"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9459(24)00603-X"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2010.00065"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.09.021"},{"key":"e_1_3_4_68_2","first-page":"99","article-title":"A comparative study of patients' preferences and sensory perceptions of three forms of inhalers among Thai asthma and COPD patients","volume":"25","author":"Bunnag C","year":"2007","unstructured":"Bunnag C, , Fuangtong R, , Pothirat C, , and Punyaratabandhu P: A comparative study of patients' preferences and sensory perceptions of three forms of inhalers among Thai asthma and COPD patients. Asian Pac J Allergy Immunol. 2007; 25:99\u2013109.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.94.07020342"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1089\/0894268041457174"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62059-5"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.04.019"},{"key":"e_1_3_4_73_2","first-page":"239","article-title":"Fluticasone\/formoterol pressurized metered-dose inhaler: An assessment of patient preference and usability in adolescent and adult patients with obstructive lung disease","volume":"2","author":"Bell D","year":"2015","unstructured":"Bell D, , Mansfield L, , Lomax M, , and Dissanayake S: Fluticasone\/formoterol pressurized metered-dose inhaler: An assessment of patient preference and usability in adolescent and adult patients with obstructive lung disease. RDD Europe 2015. 2015; 2:239\u2013244.","journal-title":"RDD Europe 2015"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.04.010"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1006\/pupt.2001.0273"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802637862"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.03213"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1089\/jam.1999.12.177"},{"key":"e_1_3_4_79_2","first-page":"27","article-title":"The CASE survey: Patient and physician perceptions regarding asthma medication use and associated oropharyngeal symptoms","volume":"15","author":"Fitzgerald JM","year":"2008","unstructured":"Fitzgerald JM, , Chan CK, , Holroyde MC, , and Boulet LP: The CASE survey: Patient and physician perceptions regarding asthma medication use and associated oropharyngeal symptoms. Can Respir J. 2008; 15:27\u201332.","journal-title":"Can Respir J"},{"key":"e_1_3_4_80_2","first-page":"505","article-title":"An audit of inhaler technique among asthma patients of 34 general practitioners","volume":"40","author":"Hilton S","year":"1990","unstructured":"Hilton S: An audit of inhaler technique among asthma patients of 34 general practitioners. Br J Gen Pract. 1990; 40:505\u2013506.","journal-title":"Br J Gen Pract"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.48.6.603"},{"key":"e_1_3_4_82_2","unstructured":"Seretide Evohaler Summary of Product Characteristics. Available at: www.medicines.org.uk\/emc\/medicine\/2914; Accessed April3 2015."},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0989-9"},{"key":"e_1_3_4_84_2","first-page":"726s","article-title":"Fluticasone propionate\/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma","volume":"38","author":"Price D","year":"2011","unstructured":"Price D, , Papi A, , Kaiser K, , Grothe B, , and Lomax M: Fluticasone propionate\/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma. Eur Respir J, 2011; 38:726s.","journal-title":"Eur Respir J"},{"key":"e_1_3_4_85_2","unstructured":"Flutiform Summary of Product Characteristics. Available at: www.medicines.org.uk\/emc\/medicine\/26954; Accessed April3 2015."},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.1.335"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.08530338"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20767"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004124"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.4.1036"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.4.1134"},{"key":"e_1_3_4_92_2","first-page":"135","article-title":"Acceptance of the Accuhaler, a multi-dose powder inhaler, among asthmatic patients: A comparison with the pressurized metered-dose inhaler","volume":"18","author":"Liam CK","year":"2000","unstructured":"Liam CK, , Lim KH, , and Wong CM: Acceptance of the Accuhaler, a multi-dose powder inhaler, among asthmatic patients: A comparison with the pressurized metered-dose inhaler. Asian Pac J Allergy Immunol. 2000; 18:135\u2013140.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2011.587579"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01138.x"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.3132\/pcrj.2007.00081"},{"key":"e_1_3_4_96_2","unstructured":"Global Initiative for Asthma (GINA): GINA Report Global Strategy for Asthma Management and Prevention. http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINA_Report_2015_Aug11.pdf; accessed September2015."},{"key":"e_1_3_4_97_2","first-page":"1369","article-title":"Inhaler therapy for adults with obstructive lung diseases: Powder or aerosol?","volume":"142","author":"Dekhuijzen PN","year":"1998","unstructured":"Dekhuijzen PN: Inhaler therapy for adults with obstructive lung diseases: Powder or aerosol?. Ned Tijdschr Geneeskd. 1998; 142:1369\u20131374.","journal-title":"Ned Tijdschr Geneeskd"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2015.1232","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2015.1232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2015.1232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:46:19Z","timestamp":1779191179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2015.1232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,29]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8,1]]}},"alternative-id":["10.1089\/jamp.2015.1232"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2015.1232","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,29]]}}}